Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05720117 · ClinicalTrials.gov registry record · Phase 1
A Study of PYX-201 in Advanced Solid Tumors
A Phase 1 study of Solid Tumor and Advanced Solid Tumor, sponsored by Pyxis Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT05720117: Recruiting Phase 1 study of Solid Tumor and Advanced Solid Tumor, sponsored by Pyxis Oncology.
NCT05720117 is a Phase 1 study of Solid Tumor and Advanced Solid Tumor that is actively recruiting participants, run by Pyxis Oncology. The registered enrollment target is 330 participants, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05720117, a Phase 1 study of Solid Tumor and Advanced Solid Tumor, is actively recruiting participants, sponsored by Pyxis Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Primary Outcome
DLT is defined as (1) an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs after the treatment with PYX-201 and (2) meets any of the predefined criteria outlined in the protocol.
Conditions Studied
Interventions
- DRUG PYX-201
Study Locations (20)
Texas
- NEXT Dallas - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
- NEXT San Antonio - San Antonio
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Brussels Capital
- Institut Jules Bordet - Brussels
- Cliniques Universitaires Saint-Luc - Brussels
Arizona
- HonorHealth Research Institute - Scottsdale
California
- Ronald Reagan UCLA Medical Center - Los Angeles
Colorado
- SCRI - HealthOne Denver - Denver
Florida
- SCRI - Florida Cancer Specialists - Sarasota
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
What NCT05720117 shows while recruiting
NCT05720117 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (50% higher).
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PYX-201 is the first listed.
NCT05720117 names 20 study sites across 16 states, led by Texas, Massachusetts, Brussels Capital.
Frequently Asked Questions
What is clinical trial NCT05720117 about?
NCT05720117 is a clinical study titled "A Study of PYX-201 in Advanced Solid Tumors". The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
What is the current status of trial NCT05720117?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 330 participants. The study started on 2023-03-14. Estimated completion is 2027-05.
What conditions does trial NCT05720117 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Solid Tumor.
What interventions are being tested in trial NCT05720117?
The interventions under investigation include: PYX-201 (DRUG).
Who is sponsoring clinical trial NCT05720117?
This trial is sponsored by Pyxis Oncology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05720117 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05720117's enrollment target sits among peer trials
330 18th of 196 higher than 178 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI